Greater Philadelphia continues to emerge as a hotbed for medical device and biotech innovation, producing nimble startups that are advancing solutions for vision restoration, pain management, and critical manufacturing processes. Three such companies recently presented at the 2nd Annual Kymanox Showcase in Cary, NC. Each is advancing sophisticated technologies while staying lean, hitting key milestones, and attracting capital — all with the strategic support of Kymanox’s King of Prussia Device Lab and its proven hyper-virtual model.
In today’s life sciences market, flexibility and lean operations have become essential for survival and success. With capital more selective, development timelines under pressure, and regulatory and manufacturing hurdles as high as ever, startups that can scale expertise on demand — without heavy fixed overhead or bloated teams — are the ones that move faster, de-risk more effectively, and stretch every dollar further. This lean commercialization approach allows founders to stay focused on science, clinical progress, and investor conversations rather than getting weighed down by internal infrastructure.
What stands out is that these founders are staying lean, hitting key milestones, and attracting sophisticated capital — all while keeping overhead low and execution speed high.
BioLattice Ophthalmics: Synthetic Corneal Implants to Restore Vision Without Donor Tissue
Linda Alunkal, CEO and co-founder of Philadelphia-based BioLattice Ophthalmics, is addressing corneal blindness, which affects millions of patients worldwide. Current standard-of-care treatments rely on donor corneas paired with lifelong immunosuppressants that frequently lead to rejection and blindness again within 15 years. BioLattice is developing a purely synthetic, cell-free permanent corneal implant — a high-precision, biocompatible device designed for seamless integration without the risks associated with donor tissue.
Alunkal, a chemical engineer with over 20 years of industry experience, emphasized the extreme precision required: even millimeter-level errors can cause implant failure in patients who may already be blind in one eye. The company has completed multiple pilot animal studies and is advancing toward GLP studies, with IND-related workstreams underway. Alunkal recently stepped into the CEO role (with inventor Dr. Amelia Zellander shifting to CSO), and the team has raised over $1 million in dilutive funding while actively closing a $2.5 million round — with the first close completed and approximately 80% of the round already spoken for.
Kymanox’s King of Prussia team has acted as a critical extension of BioLattice’s capabilities, delivering the engineering precision, process development, and regulatory guidance needed to maintain tight timelines without the overhead of a large internal team. This lean commercialization approach has allowed BioLattice to focus leadership energy on science, clinical progress, and fundraising while advancing a technology with global patient impact.
Balanced Pharma: Redefining Dental Anesthesia with Faster, Less Painful Buffered Formulations
Scott Keadle, founder and CEO of Balanced Pharma and a dentist with decades of clinical experience, is solving one of the most common patient complaints in dentistry: the painful burning sensation caused by highly acidic local anesthetics. Traditional formulations are roughly 25,000 times more acidic than human tissue, leading to injection pain, slower onset, and reduced efficacy. Balanced Pharma’s patented cartridge technology removes the acid at the point of use while preserving full shelf-life, safety, and duration — delivering faster onset, better numbing, and dramatically reduced discomfort with no change to a dentist’s workflow.
Momentum is building quickly. Dental Economics recently declared buffered anesthetics “the new standard of care,” and key opinion leaders have responded enthusiastically. In the past 12 months, the company has achieved roughly 20 of the 25 hardest milestones to market and raised approximately $8 million in its current round (including a strategic investment from global dental leader Septodont, whose COO joined the board). Total funding now stands at around $12 million with strong participation from dentists and industry insiders.
Kymanox’s King of Prussia Device Lab has functioned almost as an extended founding team, providing combination product engineering, regulatory strategy, and project management support. This partnership has enabled Balanced Pharma to de-risk development efficiently and maintain focus on commercialization without building a large internal organization.
SterilMetric Innovations: Real-Time Sensing to Transform Ethylene Oxide Sterilization
Nicholas Ciccarelli, Chief Operating Officer at Kymanox and a leader at SterilMetric Innovations (a Kymanox spin-out), presented a solution to one of medtech’s most persistent but under-the-radar challenges: validating ethylene oxide (EtO) sterilization, the method used for roughly $50 billion worth of medical devices annually.
Unlike steam or radiation methods — where parameters can be measured directly — EtO sterilization has historically been a trial-and-error process relying on biological indicators. SterilMetric’s industrial sensor (roughly the size of a Coke can and intrinsically safe for explosive EtO environments) can be placed directly inside product packaging to deliver real-time, spatial mapping of gas concentration throughout massive sterilization chambers. The technology is already drawing strong interest from major sterilization service providers.
As a spin-out born from Kymanox’s internal innovation pipeline, SterilMetric has progressed from early feasibility testing to near-commercial prototypes with minimal external capital. The company benefits directly from Kymanox’s rare concentration of sterilization expertise and the King of Prussia Device Lab’s capabilities in electrical, optical, thermal management, and prototyping. Ciccarelli noted that the sensor and supporting software ecosystem are IP-protected and positioned to turn a decades-old “cross-your-fingers” process into a precise, data-driven standard.
Eastern Pennsylvania’s Rising Medtech and Biotech Momentum
These three companies — BioLattice Ophthalmics, Balanced Pharma, and SterilMetric Innovations — highlight the tremendous medical device and biotech innovation emerging from the Eastern Pennsylvania region. Whether headquartered locally or deeply partnered with regional infrastructure, they are advancing complex technologies while operating lean and raising meaningful capital.
With Kymanox’s King of Prussia Device Lab – a 5,000-square-foot cGMP hub for device design, prototyping, human factors testing, and clinical-stage manufacturing – and expert team right in the backyard, these startups gain on-demand access to specialized engineering, regulatory expertise, combination product know-how, and clinical-stage manufacturing capabilities. The result is faster iteration, significantly de-risked development, and the ability for founders to concentrate on science, clinical progress, and investor conversations rather than building large internal organizations.
As Eastern Pennsylvania’s life sciences ecosystem continues to strengthen, this lean commercialization model — backed by deep local expertise — is proving to be a powerful formula for moving promising technologies from concept to patients more quickly and efficiently than traditional approaches allow.
